| Weight | 1 lbs |
|---|---|
| Dimensions | 9 × 5 × 2 in |
| target | Parvovirus B19 reactive IgG |
| species reactivity | Parvovirus |
| applications | ELISA |
| assay type | Indirect & quantitative |
| available size | 3 mL |
Parvovirus B19 IgG Control Serum BC122G
$94.00
Summary
- Virion/Serion Diagnostic Kit Control for research use (RUO)
- Parvovirus
- Applications: ELISA
- IgG control serum
- Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
- 3 mL
Parvovirus B19 IgG Control Serum BC122G
| target relevance |
|---|
| Organism Parvovirus B19 |
| Structure and strains Human parvovirus B19, generally referred to as B19 virus (B19V), parvovirus B19 or sometimes erythrovirus B19, is the first (and until 2005 the only) known human virus in the family Parvoviridae, genus Erythroparvovirus; it measures only 23 26 nm in diameter. Human parvovirus b19 is a below-species classification of Erythroparvovirus primate1. The name is derived from Latin parvum, meaning small, reflecting the fact that B19 ranks among the smallest DNA viruses. B19 virus is most known for causing disease in the pediatric population; however, it can also affect adults. It is the classic cause of the childhood rash called fifth disease or erythema infectiosum, or "slapped cheek syndrome". |
| Disease With a diameter of 18-26 nm, the worldwide distributed Parvovirus B19 belongs to the smallest human pathogens. Its capsid is made up of 95% of the structural protein VP2. The remaining 5% consists of VP1. In many cases, Parvovirus B19 infections remain clinically asymptomatic. Infected children may develop erythema infectiosum, also named fifth disease. After an incubation period of four to 14 days garland-shaped exanthemas spread from the face downwards. The rash, in adults possibly accompanied by arthralgia in the small joints, may last for up to three weeks. Current studies in Germany indicate that 10-20% of children under three years of age have already had an infection with the virus. In adults, the seroprevalence increases to 70%. In pregnant women with primary Parvovirus B19 infection the virus is transmitted to the fetus and may lead to severe complications. In general, the regular course of an infection is limited by the synthesis of neutralizing antibodies. In immunosuppressed patients or patients with chronic haemolytic anaemia, infection may elicit severe clinical consequences with aplastic crisis, which can have fatal consequences. |
| Detection and diagnosis As a consequence of the variable clinical symptoms which may be associated with Parvovirus B19 infection, a clinical diagnosis should be supported by the demonstration of virus specific antibodies. |
Data
Publications
Publications
| pmid | title | authors | citation |
|---|---|---|---|
| We haven't added any publications to our database yet. | |||
Protocols
| relevant to this product |
|---|
| BC122G protocol |
Documents
| # | ||
|---|---|---|
| Please enter your product and batch number here to retrieve product datasheet, SDS, and QC information. | ||
